Clicky

Oscotec Inc(039200)

Description: Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.


Keywords: Medicine Drug Discovery Alzheimer's Disease Rheumatoid Arthritis Arthritis Non Small Cell Lung Cancer Acute Myeloid Leukemia Osteoporosis Treatment Of Acute Myeloid Leukemia Treatment Of Alzheimer's Disease Aif Immune Thrombocytopenia Syk Cd135 Tyrosine Kinases Flt3

Home Page: www.oscotec.com

A Building, Korea Bio Park
Seongnam-si, 13488
South Korea
Phone: 82 3 1628 7666


Officers

Name Title
Sung-Hee Son Exec. Officer
Se-Nyun Kim Exec. Officer
Hirose Dakashi Exec. Officer
Su-Sung Lee Exec. Officer
So-Jin Ahn Exec. Officer
Ju-Won Kim Exec. Officer
Jae-Sang Lee Exec. Officer
Sung-Ho Park Exec. Officer
Seung-Chul Lee Exec. Officer
Mr. Jeung-Keun Kim Chief Exec. Officer

Exchange: KQ

Country: KR

Currency: Korean Won (₩)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0
Price-to-Sales TTM: 18.5373
IPO Date: 2007-01-17
Fiscal Year End: December
Full Time Employees: 0
Back to stocks